User login
TELL PATIENTS that parvovirus infections before 20 weeks’ gestation confer a risk of fetal morbidity and mortality as high as 16%, but don’t significantly increase long-term developmental sequelae (strength of recommendation [SOR]: B, prospective cohort studies).
Parvovirus infection rates are similar in a variety of maternal workplace environments (SOR: A, prospective cohort studies); routinely excluding pregnant women from the workplace is unwarranted (SOR: C, expert opinion).
Physicians should order immunologic assays for women who may have been exposed to parvovirus to assess maternal immunity and determine whether evaluation for fetal hydrops is necessary (SOR: C, expert opinion).
Evidence summary
Although most parvovirus infections in pregnant women don’t harm the fetus, human parvovirus B19 (B19V) may cause severe fetal anemia and cardiac failure, potentially leading to nonimmune fetal hydrops. Transplacental transmission occurs in as many as 33% of cases, with the highest risk of fetal infection occurring between the 9th and 20th weeks of gestation and within 2 to 4 weeks of maternal infection.1,2
A quarter of infections are asymptomatic; the remainder present as a self-limited flu-like syndrome. Infected people may transmit the virus for 5 to 10 days before developing symptoms.1-3
Infection raises risk of death, but not later developmental delay
First- and second-trimester parvovirus infections carry an excess fetal loss risk of 10% above baseline (5%), but a low risk of long-term sequelae during childhood.4 A prospective cohort study of 1018 pregnant German women, confirmed to be immunoglobulin M-positive and followed by targeted ultrasound for 10 weeks, found a 6.3% incidence of fetal death and a 3.9% incidence of hydrops fetalis.3 Fetal death occurred only with B19V infection before 20 weeks’ gestation. Although more cases (67.5%) of fetal hydrops occurred before 20 weeks, cases were seen throughout all gestational periods.
A similar prospective cohort study of 427 pregnant women from England and Wales reported 14% and 1.7% incidences of fetal death and hydrops fetalis, respectively.4 In following up on 182 infants (1 year of age) and 129 children (7-10.5 years of age), investigators found 3 children (2%) with developmental delays in each cohort—consistent with expected numbers for any unselected group of children. They found no congenital abnormalities attributable to B19V infections.
Occupational exposure doesn’t pose significant danger
Few prospective studies have examined prevention of parvovirus infection because of the difficulty of detecting infection during the initial asymptomatic phase. In an effort to determine potential modifiable risk factors, a prospective cohort study of a convenience sample at a referral clinic with no power analysis examined infection rates among 618 pregnant women in various occupations who were exposed to infected children.5
Exposure to children in the household produced the highest risk of infection (29.4% vs 16.7% overall incidence; P<.001). Primary school teachers and daycare workers had an increased risk of infection that didn’t reach statistical significance (23%, P=.5).5 None of the occupations examined (school teacher, daycare worker, office professional, homemaker, and health care worker) demonstrated significantly increased risk (P=.5). Because of the lack of difference in infection rates among studied occupations, the authors recommended against routine workplace exclusion.5 Subsequent Danish population-based cohort studies (N=32,300) found that nursery school teachers had an odds ratio of 3.0 for acute infection, but it was reduced to 1.82 after accounting for infections in their own children.6
The TABLE summarizes current consensus guidelines for initial evaluation, clinical surveillance, and management of pregnant women potentially exposed to B19V.2
TABLE
Managing suspected parvovirus B19 infections in pregnancy: Consensus recommendations
| Antibody results | Status | Clinical follow-up |
|---|---|---|
| IgG-positive, IgM-negative | Immune | Reassurance |
| IgG-negative, IgM-negative | Susceptible | Repeat immunologic assay in 2-4 wk |
| IgG-negative, IgM-positive | Infection in previous 7 days | Refer to MFM for consultation and targeted ultrasound every 4 wk for 12 wk to evaluate for fetal hydrops |
| IgG-positive, IgM-positive | Infection within previous 7-120 days | |
| IgG, immunoglobulin G; IgM, immunoglobulin M; MFM, maternal-fetal-medicine specialist. Adapted from: Goff M. J Midwifery Women’s Health. 2005.2 | ||
Recommendations
The Centers for Disease Control and Prevention and a 2000 practice bulletin from the American College of Obstetricians and Gynecologists (ACOG) don’t recommend routinely excluding pregnant women from the workplace during endemic outbreaks of parvovirus to reduce exposure risk. They do, however, encourage women to discuss their individual risk with their physician.7,8
ACOG and the Society of Obstetricians and Gynaecologists of Canada concur with consensus guidelines for evaluating and managing women suspected of exposure or infection.1,7
1. Crane J. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2002;24:727-734.
2. Goff M. Parvovirus B19 in pregnancy. J Midwifery Women’s Health. 2005;50:536-538.
3. Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24:513-518.
4. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long-term outcome of human parvovirus in pregnancy. Br J Obstet Gynaecol. 1998;105:174-178.
5. Harger JH, Adler SP, Koch WC, et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91:413-420.
6. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999;281:1099-1105.
7. Centers for Disease Control and Prevention. Parvovirus B19 infection and pregnancy. Available at: www.cdc.gov/ncidod/dvrd/revb/respiratory/b19&preg.htm. Accessed August 2, 2010.
8. American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. ACOG Practice Bulletin No. 20. September 2000. Available at: www.acog.org/publications/educational_bulletins/pb020.cfm. Accessed August 2, 2010.
TELL PATIENTS that parvovirus infections before 20 weeks’ gestation confer a risk of fetal morbidity and mortality as high as 16%, but don’t significantly increase long-term developmental sequelae (strength of recommendation [SOR]: B, prospective cohort studies).
Parvovirus infection rates are similar in a variety of maternal workplace environments (SOR: A, prospective cohort studies); routinely excluding pregnant women from the workplace is unwarranted (SOR: C, expert opinion).
Physicians should order immunologic assays for women who may have been exposed to parvovirus to assess maternal immunity and determine whether evaluation for fetal hydrops is necessary (SOR: C, expert opinion).
Evidence summary
Although most parvovirus infections in pregnant women don’t harm the fetus, human parvovirus B19 (B19V) may cause severe fetal anemia and cardiac failure, potentially leading to nonimmune fetal hydrops. Transplacental transmission occurs in as many as 33% of cases, with the highest risk of fetal infection occurring between the 9th and 20th weeks of gestation and within 2 to 4 weeks of maternal infection.1,2
A quarter of infections are asymptomatic; the remainder present as a self-limited flu-like syndrome. Infected people may transmit the virus for 5 to 10 days before developing symptoms.1-3
Infection raises risk of death, but not later developmental delay
First- and second-trimester parvovirus infections carry an excess fetal loss risk of 10% above baseline (5%), but a low risk of long-term sequelae during childhood.4 A prospective cohort study of 1018 pregnant German women, confirmed to be immunoglobulin M-positive and followed by targeted ultrasound for 10 weeks, found a 6.3% incidence of fetal death and a 3.9% incidence of hydrops fetalis.3 Fetal death occurred only with B19V infection before 20 weeks’ gestation. Although more cases (67.5%) of fetal hydrops occurred before 20 weeks, cases were seen throughout all gestational periods.
A similar prospective cohort study of 427 pregnant women from England and Wales reported 14% and 1.7% incidences of fetal death and hydrops fetalis, respectively.4 In following up on 182 infants (1 year of age) and 129 children (7-10.5 years of age), investigators found 3 children (2%) with developmental delays in each cohort—consistent with expected numbers for any unselected group of children. They found no congenital abnormalities attributable to B19V infections.
Occupational exposure doesn’t pose significant danger
Few prospective studies have examined prevention of parvovirus infection because of the difficulty of detecting infection during the initial asymptomatic phase. In an effort to determine potential modifiable risk factors, a prospective cohort study of a convenience sample at a referral clinic with no power analysis examined infection rates among 618 pregnant women in various occupations who were exposed to infected children.5
Exposure to children in the household produced the highest risk of infection (29.4% vs 16.7% overall incidence; P<.001). Primary school teachers and daycare workers had an increased risk of infection that didn’t reach statistical significance (23%, P=.5).5 None of the occupations examined (school teacher, daycare worker, office professional, homemaker, and health care worker) demonstrated significantly increased risk (P=.5). Because of the lack of difference in infection rates among studied occupations, the authors recommended against routine workplace exclusion.5 Subsequent Danish population-based cohort studies (N=32,300) found that nursery school teachers had an odds ratio of 3.0 for acute infection, but it was reduced to 1.82 after accounting for infections in their own children.6
The TABLE summarizes current consensus guidelines for initial evaluation, clinical surveillance, and management of pregnant women potentially exposed to B19V.2
TABLE
Managing suspected parvovirus B19 infections in pregnancy: Consensus recommendations
| Antibody results | Status | Clinical follow-up |
|---|---|---|
| IgG-positive, IgM-negative | Immune | Reassurance |
| IgG-negative, IgM-negative | Susceptible | Repeat immunologic assay in 2-4 wk |
| IgG-negative, IgM-positive | Infection in previous 7 days | Refer to MFM for consultation and targeted ultrasound every 4 wk for 12 wk to evaluate for fetal hydrops |
| IgG-positive, IgM-positive | Infection within previous 7-120 days | |
| IgG, immunoglobulin G; IgM, immunoglobulin M; MFM, maternal-fetal-medicine specialist. Adapted from: Goff M. J Midwifery Women’s Health. 2005.2 | ||
Recommendations
The Centers for Disease Control and Prevention and a 2000 practice bulletin from the American College of Obstetricians and Gynecologists (ACOG) don’t recommend routinely excluding pregnant women from the workplace during endemic outbreaks of parvovirus to reduce exposure risk. They do, however, encourage women to discuss their individual risk with their physician.7,8
ACOG and the Society of Obstetricians and Gynaecologists of Canada concur with consensus guidelines for evaluating and managing women suspected of exposure or infection.1,7
TELL PATIENTS that parvovirus infections before 20 weeks’ gestation confer a risk of fetal morbidity and mortality as high as 16%, but don’t significantly increase long-term developmental sequelae (strength of recommendation [SOR]: B, prospective cohort studies).
Parvovirus infection rates are similar in a variety of maternal workplace environments (SOR: A, prospective cohort studies); routinely excluding pregnant women from the workplace is unwarranted (SOR: C, expert opinion).
Physicians should order immunologic assays for women who may have been exposed to parvovirus to assess maternal immunity and determine whether evaluation for fetal hydrops is necessary (SOR: C, expert opinion).
Evidence summary
Although most parvovirus infections in pregnant women don’t harm the fetus, human parvovirus B19 (B19V) may cause severe fetal anemia and cardiac failure, potentially leading to nonimmune fetal hydrops. Transplacental transmission occurs in as many as 33% of cases, with the highest risk of fetal infection occurring between the 9th and 20th weeks of gestation and within 2 to 4 weeks of maternal infection.1,2
A quarter of infections are asymptomatic; the remainder present as a self-limited flu-like syndrome. Infected people may transmit the virus for 5 to 10 days before developing symptoms.1-3
Infection raises risk of death, but not later developmental delay
First- and second-trimester parvovirus infections carry an excess fetal loss risk of 10% above baseline (5%), but a low risk of long-term sequelae during childhood.4 A prospective cohort study of 1018 pregnant German women, confirmed to be immunoglobulin M-positive and followed by targeted ultrasound for 10 weeks, found a 6.3% incidence of fetal death and a 3.9% incidence of hydrops fetalis.3 Fetal death occurred only with B19V infection before 20 weeks’ gestation. Although more cases (67.5%) of fetal hydrops occurred before 20 weeks, cases were seen throughout all gestational periods.
A similar prospective cohort study of 427 pregnant women from England and Wales reported 14% and 1.7% incidences of fetal death and hydrops fetalis, respectively.4 In following up on 182 infants (1 year of age) and 129 children (7-10.5 years of age), investigators found 3 children (2%) with developmental delays in each cohort—consistent with expected numbers for any unselected group of children. They found no congenital abnormalities attributable to B19V infections.
Occupational exposure doesn’t pose significant danger
Few prospective studies have examined prevention of parvovirus infection because of the difficulty of detecting infection during the initial asymptomatic phase. In an effort to determine potential modifiable risk factors, a prospective cohort study of a convenience sample at a referral clinic with no power analysis examined infection rates among 618 pregnant women in various occupations who were exposed to infected children.5
Exposure to children in the household produced the highest risk of infection (29.4% vs 16.7% overall incidence; P<.001). Primary school teachers and daycare workers had an increased risk of infection that didn’t reach statistical significance (23%, P=.5).5 None of the occupations examined (school teacher, daycare worker, office professional, homemaker, and health care worker) demonstrated significantly increased risk (P=.5). Because of the lack of difference in infection rates among studied occupations, the authors recommended against routine workplace exclusion.5 Subsequent Danish population-based cohort studies (N=32,300) found that nursery school teachers had an odds ratio of 3.0 for acute infection, but it was reduced to 1.82 after accounting for infections in their own children.6
The TABLE summarizes current consensus guidelines for initial evaluation, clinical surveillance, and management of pregnant women potentially exposed to B19V.2
TABLE
Managing suspected parvovirus B19 infections in pregnancy: Consensus recommendations
| Antibody results | Status | Clinical follow-up |
|---|---|---|
| IgG-positive, IgM-negative | Immune | Reassurance |
| IgG-negative, IgM-negative | Susceptible | Repeat immunologic assay in 2-4 wk |
| IgG-negative, IgM-positive | Infection in previous 7 days | Refer to MFM for consultation and targeted ultrasound every 4 wk for 12 wk to evaluate for fetal hydrops |
| IgG-positive, IgM-positive | Infection within previous 7-120 days | |
| IgG, immunoglobulin G; IgM, immunoglobulin M; MFM, maternal-fetal-medicine specialist. Adapted from: Goff M. J Midwifery Women’s Health. 2005.2 | ||
Recommendations
The Centers for Disease Control and Prevention and a 2000 practice bulletin from the American College of Obstetricians and Gynecologists (ACOG) don’t recommend routinely excluding pregnant women from the workplace during endemic outbreaks of parvovirus to reduce exposure risk. They do, however, encourage women to discuss their individual risk with their physician.7,8
ACOG and the Society of Obstetricians and Gynaecologists of Canada concur with consensus guidelines for evaluating and managing women suspected of exposure or infection.1,7
1. Crane J. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2002;24:727-734.
2. Goff M. Parvovirus B19 in pregnancy. J Midwifery Women’s Health. 2005;50:536-538.
3. Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24:513-518.
4. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long-term outcome of human parvovirus in pregnancy. Br J Obstet Gynaecol. 1998;105:174-178.
5. Harger JH, Adler SP, Koch WC, et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91:413-420.
6. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999;281:1099-1105.
7. Centers for Disease Control and Prevention. Parvovirus B19 infection and pregnancy. Available at: www.cdc.gov/ncidod/dvrd/revb/respiratory/b19&preg.htm. Accessed August 2, 2010.
8. American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. ACOG Practice Bulletin No. 20. September 2000. Available at: www.acog.org/publications/educational_bulletins/pb020.cfm. Accessed August 2, 2010.
1. Crane J. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2002;24:727-734.
2. Goff M. Parvovirus B19 in pregnancy. J Midwifery Women’s Health. 2005;50:536-538.
3. Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24:513-518.
4. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long-term outcome of human parvovirus in pregnancy. Br J Obstet Gynaecol. 1998;105:174-178.
5. Harger JH, Adler SP, Koch WC, et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91:413-420.
6. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999;281:1099-1105.
7. Centers for Disease Control and Prevention. Parvovirus B19 infection and pregnancy. Available at: www.cdc.gov/ncidod/dvrd/revb/respiratory/b19&preg.htm. Accessed August 2, 2010.
8. American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. ACOG Practice Bulletin No. 20. September 2000. Available at: www.acog.org/publications/educational_bulletins/pb020.cfm. Accessed August 2, 2010.
Evidence-based answers from the Family Physicians Inquiries Network